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ABSTRACT 20 
Urothelial bladder cancer is a common cancer associated with considerable burden for both patients 21 
and healthcare providers alike. The majority of patients present with non-muscle-invasive bladder 22 
cancer (NMIBC) which, although not immediately life-threatening, requires appropriate initial 23 
management and long-term surveillance which is both invasive and costly. Accurate diagnostic 24 
urinary biomarkers could be transformational in this setting, yet have proved to be a significant 25 
challenge to bladder cancer scientists over the last two decades. Such biomarkers would need to 26 
represent a range of tumour grades and stages, encompass inter- and intra-tumour heterogeneity, 27 
and compete with the current diagnostic gold standard of cystoscopy with a sensitivity and 28 
specificity of 85% and 87%, respectively. For the field to move forward in this current exciting era of 29 
high-throughput proteomics and genomics, bladder cancer scientists need to find a consensus on 30 
the optimal urinary substrate (DNA, RNA, protein, etc) and deliver robust well-designed studies in 31 
the correct populations with appropriate statistical input. Issues relating to tumour heterogeneity 32 
and anticipatory diagnosis also require considerable thought. The challenge remains unchanged.  33 
FOCAL POINTS 34 
 Accurate urinary biomarkers for the diagnosis of urothelial bladder cancer could be 35 
transformational for patients and healthcare providers alike. 36 
 To date, despite several FDA approvals, no such markers are routinely used in the clinical 37 
setting. 38 
 Poor study design and non-representative study populations are major contributory factors 39 
and recent systematic reviews have highlighted such weaknesses. 40 
 Low grade and low stage tumours are common, yet the most difficult to diagnose non-41 
invasively; however, they should be incorporated into study populations in proportions 42 
representative of the incident and/or recurrent disease patient setting to avoid bias.  43 
 Promising urinary biomarker substrates include proteins and nucleic acids, with inherent 44 
strengths and weaknesses. 45 
 Enduring challenges remain inter- and intra-tumour heterogeneity, and anticipatory 46 
diagnosis. 47 
 48 
  49 
COMMENTARY 50 
Urothelial bladder cancer (UBC) is the seventh commonest cancer in Western societies [1], resulting 51 
in 69,000 and 180,000 new cases per year in the USA and EU, respectively. The vast majority of new 52 
cases are diagnosed following single or repeated episodes of haematuria (blood in the urine) which 53 
is investigated by cystoscopy (inserting a “telescope” via the urethra into the bladder) and around 54 
10% of patients investigated for haematuria will be diagnosed with UBC [2]. Following initial 55 
treatment by transurethral resection of bladder tumour, 75-85% of these patients will be diagnosed 56 
with non-muscle-invasive tumours (NMIBC, stages pTa/pT1/pTis), and the remainder muscle-57 
invasive tumours (MIBC, stages pT2-4) [3]. Thereafter, treatment strategies differ markedly: patients 58 
with MIBC are likely to undergo more radical therapy with combinations of chemotherapy and 59 
radiotherapy or cystectomy (removal of the bladder) [4], whereas those with NMIBC will be treated 60 
with intravesical therapy (therapies delivered into the bladder) followed by cystoscopic surveillance 61 
(regular inspection of the bladder) [5]. Schedules of cystoscopic surveillance (and the nature of 62 
intravesical therapy) are determined by the risk category of NMIBC (low-, intermediate- or high-risk) 63 
[5]. With disease recurrence a lifetime risk across all NMIBC categories (up to 80% [6]), and 64 
progression to MIBC an important consideration for high-risk NMIBC patients (up to 45% [6;7]), 65 
cystoscopic surveillance represents the mainstay of longer term management for all NMIBC patients. 66 
Urine cytology is often used as an adjunct to cystoscopy: the microscopic detection of cancer cells in 67 
the urine is a very specific indicator of UBC but has poor sensitivity for low-grade UBC, resulting in 68 
low overall sensitivity [8]. 69 
Cystoscopy is invasive and burdensome for patients and expensive for healthcare providers [9;10], 70 
such that from diagnosis to death on a per patient basis UBC is one of the most expensive 71 
malignancies to manage [11]. Therefore, non-invasive or urinary biomarkers for the accurate and 72 
reliable detection of urothelial bladder cancer (UBC) have the potential to be transformational for 73 
both UBC patients and healthcare providers by reducing reliance on cystoscopy for diagnosis and 74 
surveillance. Furthermore, this setting is fertile yet challenging ground for translational medicine. 75 
Since UBCs are in direct contact with urine, urine is considered to be a promising biospecimen for 76 
developing non-invasive tests to detect and characterise bladder tumours. However, UBCs are highly 77 
heterogeneous with high mutational burden and variable copy number aberrations and gene 78 
expression profiles [12;13]; thus, different tumours may release different biomarkers (necessitating 79 
multimarker tests), and early-stage and low-grade tumours may only release very small amounts of 80 
such markers, potentially impairing test sensitivity [14]. Markers must also be highly tumour-specific 81 
so that haematuria itself and other non-malignant conditions do not generate false positives [14;15].  82 
In the search for better urinary biomarkers genomic, proteomic and metabolomic approaches have 83 
all yielded promising results [14;16-19]. Despite such work over several decades [20], a 2015 84 
WHO/ICUD consensus stated that [8]: 85 
 Despite considerable advances in recent years, the authors feel that at this stage the added value 86 
of molecular markers for the diagnosis of urothelial tumors has not yet been identified. 87 
 Current data suggest that some of these markers may have the potential to play a role in 88 
screening and surveillance of bladder cancer. 89 
 Well-designed protocols and prospective, controlled trials will be needed to provide the basis to 90 
determine whether integration of molecular markers into clinical decision-making will be of value 91 
in the future. 92 
We recently undertook a systematic review of diagnostic and prognostic urinary protein biomarkers 93 
and formed similar conclusions [20], principally that: 94 
 The majority of urine biomarker studies contain bias or are insufficiently reported. 95 
 The urinary concentrations of a large number of proteins are increased by the presence of 96 
bladder cancer, but most proteins are not increased in all cases and are not specific to bladder 97 
cancer. 98 
 NMP22, BTA, UBC and Cyfra 21-1 are the only well-validated urinary protein biomarkers and 99 
their sensitivities and specificities are well below those of cystoscopy. 100 
We considered our approach to this systematic review to be stringent yet pragmatic [20], such that 101 
it would provide a useful resource for workers in the field. We applied a number of criteria to define 102 
whether individual studies provided “equivocal” or “unequivocal data” regarding a particular 103 
biomarker(s) [20]. Unequivocal data were generated by studies which comprised of ≥20 cancer 104 
patients and ≥20 controls; sensitivity and specificity had to be reported. Importantly, we also 105 
required unequivocal studies to comprise ≥25% stage pTa tumours (generally, smaller tumours and 106 
more difficult to detect non-invasively, and whose incidence is c.50% [3;21]) and ≥15% grade 1 107 
tumours (the least cellularly and molecularly abnormal tumours [13] so also difficult to detect, and 108 
whose incidence is c.25% [21]). These parameters ensured that the selected unequivocal studies had 109 
to possess an element of statistical relevance, and also be representative of a normal UBC patient 110 
population. Furthermore, if unequivocal data were generated from ≥3 studies, then we considered 111 
the biomarker data to be validated.   112 
We also classified the identified proteins as either “possible” or “unlikely” biomarkers dependent 113 
upon whether the combined sensitivity and specificity was ≥80% or <80%, respectively. White light 114 
cystoscopy is currently the gold standard detection method for UBC, the reported sensitivity and 115 
specificity of which vary greatly but a 2012 meta-analysis arrived at values of 85 and 87%, 116 
respectively [22]; any urinary biomarker would need to match or improve upon cystoscopy to be 117 
acceptable to patients and urologists. Hence, we were permissive in our definition of a possible 118 
biomarker. Yet, as described, very few studies could be considered as unequivocal, although these 119 
studies did report several possible biomarkers: fibronectin, clusterin, CEACAM1, apolipoprotein A4, 120 
calprotectin, CD147, coronin-1A, DJ-1, reg-1, stathmin-1, and γ-synuclein [20].   121 
We specifically limited our review to soluble urinary proteins as historically this has been the main 122 
focus of UBC urinary biomarker research. Additionally, with the technology currently available, they 123 
are the easiest class of biomolecule to use for point-of-care testing or to combine in an economical 124 
single multiplex assay for the detection of UBC (should a suitable biomarker panel be determined).  125 
We also envisage that measuring volatile metabolites [23], or advances in DNA sequencing may 126 
allow point-of-care testing in the not too distant future. In fact, recent publications make a strong 127 
case for DNA-based biomarkers being the frontrunners in the race to reduce reliance on cystoscopy 128 
[24-28]. Although the amount of DNA that can be extracted from urine is low and variable, PCR and 129 
advanced analysis techniques such as next generation sequencing allow identification of tiny 130 
amounts of tumour DNA in the majority of urine samples, even in the presence of an excess of non-131 
tumour DNA [27]. Genome wide copy number changes in urinary DNA, microsatellite analysis, 132 
methylation and mutations have all been used for the purpose [24-28]. Studies of urinary DNA have 133 
focussed almost exclusively on DNA extracted from the urinary cell-pellets obtained by centrifuging 134 
urine; however, we and others have found that cell-free DNA (cfDNA) in the urine supernatant 135 
contains a higher fraction of tumour DNA than cell pellet DNA, and we are optimistic that urinary 136 
cfDNA could underlie a clinically useful test for UBC detection [24;29]. As with protein biomarkers, 137 
the performance of DNA biomarkers requires thorough evaluation prior to clinical uptake, 138 
particularly in the disease surveillance setting.       139 
Whatever the biomarker substrate (proteins, nucleic acids, etc) or source (urine supernatant, cell 140 
pellet, etc), the field now needs to concentrate on designing and delivering the right studies in the 141 
right patient populations and with due statistical consideration so that evidence synthesis is robust, 142 
results are reproducible, and product marketing is not premature. Issues such as inter- and intra-143 
tumour heterogeneity should also be addressed, which may require the utilisation of biomarker 144 
panels comprised of 10s or100s of individual markers [19;24]. And the conundrum of “anticipatory” 145 
or “pre-emptive” diagnosis requires clarification - the scenario whereby a patient is urinary 146 
biomarker positive and cystoscopy negative, yet who develops recurrence within the following 12-24 147 
months. Should such patients be treated as false positive, be placed under closer surveillance, be the 148 
subject of personalised biomarkers based upon the tumour’s biomarker expression, or even be 149 
treated pre-emptively with intravesical therapies? If the biomarker is highly specific, then the latter 150 
three options could all be appropriate. The future is exciting and challenging.  151 
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Figure 1: A suggested urothelial cancer biomarker research pipeline 
 
